Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27637407 | 1.00 | BLM (0.46) | BLMLMNAPTPN1ALOX15EGFR | |
| SCHEMBL27618168 | 0.88 | ALOX15 (0.36) | BLMPTPN1ALOX15 | |
| SCHEMBL118298 | 0.85 | OR51E2 (0.34) | BLMPTPN1CA12CA1CA2 | |
| SCHEMBL116746 | 0.85 | CA12 (0.42) | LMNAKMT2ACA12CA1CA2 | |
| SCHEMBL7047394 | 0.84 | BLM (0.55) | BLMLMNAPTPN1ALOX15EGFR | |
| SCHEMBL7047501 | 0.84 | BLM (0.55) | BLMLMNAPTPN1ALOX15EGFR | |
| SCHEMBL2049449 | 0.84 | BLM (0.55) | BLMLMNAPTPN1ALOX15EGFR | |
| SCHEMBL3857379 | 0.82 | BLM (0.52) | BLMLMNAPTPN1ALOX15EGFR | |
| SCHEMBL14462537 | 0.82 | BLM (0.52) | BLMLMNAPTPN1ALOX15EGFR | |
| SCHEMBL26246047 | 0.82 | BLM (0.52) | BLMLMNAPTPN1ALOX15EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605333-B2 | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release | TRIS PHARMA, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260096986-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A FLOATING INTERPENETRATING POLYMER NETWORK FORMING SYSTEM | TRIS PHARMA INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-12569508-B2 | Antimicrobial compositions and methods of use | UNIV SOUTH AUSTRALIA (AU) | 2026-03-10 | — | — | US | disclosed |
| US-12514818-B2 | Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system | TRIS PHARMA, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250339517-A1 | LIPID NANOCARRIER VACCINE | MELBOURNE INST TECH (AU) | 2025-11-06 | — | — | US | disclosed |
| US-20250281406-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY (AU) | 2025-09-11 | — | — | US | disclosed |
| EP-4531812-A1 | LIPID NANOCARRIER VACCINE | Royal Melbourne Institute of Technology (AU) | 2025-04-09 | — | — | EP | disclosed |
| US-20250099376-A1 | PHARMACEUTICAL COMPOSITION COMPRISING GHB GASTRO-RETENTIVE RAFT FORMING SYSTEMS HAVING TRIGGER PULSE DRUG RELEASE | TRIS PHARMA, INC. (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4511065-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | Royal Melbourne Institute of Technology (AU) | 2025-02-26 | — | — | EP | disclosed |
| US-12201720-B2 | Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release | TRIS PHARMA INC (US) | 2025-01-21 | — | — | US | disclosed |
| EP-1869010-A1 | 3-SULFONYLAMINO-PYRROLIDINE-2-ONE DERIVATIVES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-12-26 | — | — | EP | disclosed |
| US-20070108405-A1 | Compositions and methods for delivery of biologically active agents | FH FAULDING & CO., LTD. (AU) | 2007-05-17 | — | — | US | disclosed |
| CN-1933813-A | Compositions and methods for delivery of biologically active agents | FH FAULDING & CO LTD (AU) | 2007-03-21 | — | — | CN | disclosed |
| EP-1534669-A4 | UREA-, GLYCERATE- AND, HYDROXYAMIDE-HEADED HYDROCARBON CHAIN LYOTROPIC PHASES FORMING SURFACTANTS | MAYNE PHARMA INT PTY LTD (AU) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006108709-A1 | 3-SULFONYLAMINO-PYRROLIDINE-2-ONE DERIVATIVES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
| EP-1667656-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | FH Faulding & Co. Limited (AU) | 2006-06-14 | — | — | EP | disclosed |
| US-20050249665-A1 | Urea-, glycerate- and, hydroxyamide-headed hydrocarbon chain lyotropic phases forming surfactants | DBL AUSTRALIA PTY LTD. (AU) | 2005-11-10 | — | — | US | disclosed |
| EP-1534669-A1 | UREA-, GLYCERATE- AND, HYDROXYAMIDE-HEADED HYDROCARBON CHAIN LYOTROPIC PHASES FORMING SURFACTANTS | DBL Australia PTY. LTD. (AU) | 2005-06-01 | — | — | EP | disclosed |
| WO-2005021046-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | FH FAULDING & CO LTD (AU) | 2005-03-10 | — | — | WO | disclosed |
| WO-2004022530-A1 | UREA-, GLYCERATE- AND, HYDROXYAMIDE-HEADED HYDROCARBON CHAIN LYOTROPIC PHASES FORMING SURFACTANTS | DBL AUSTRALIA PTY LTD (AU) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12201720-B2 | Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release | GIPR, GRPR, GHSR | BLM 3787/4885LMNA 2799/4885PTPN1 430/4885 |
| US-12569508-B2 | Antimicrobial compositions and methods of use | PCTP, PYCARD, PLIN3 | BLM 3541/4885LMNA 1586/4885PTPN1 700/4885 |
| US-20250281406-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | LIPA, LIPG, SGMS1 | BLM 281/4885LMNA 393/4885PTPN1 665/4885 |
| US-20260096986-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A FLOATING INTERPENETRATING POLYMER NETWORK FORMING SYSTEM | SI, FABP2, FABP6 | BLM 4051/4885LMNA 567/4885PTPN1 4738/4885 |
| US-12605333-B2 | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release | SI, GRPR, FABP2 | BLM 3910/4885LMNA 1386/4885PTPN1 2190/4885 |
| US-20050249665-A1 | Urea-, glycerate- and, hydroxyamide-headed hydrocarbon chain lyotropic phases forming surfactants | LIPA, HDHD5, UGCG | BLM 1559/4885LMNA 208/4885PTPN1 4110/4885 |
| US-20250099376-A1 | PHARMACEUTICAL COMPOSITION COMPRISING GHB GASTRO-RETENTIVE RAFT FORMING SYSTEMS HAVING TRIGGER PULSE DRUG RELEASE | GIPR, GRPR, GHSR | BLM 3787/4885LMNA 2799/4885PTPN1 430/4885 |
| US-20250339517-A1 | LIPID NANOCARRIER VACCINE | CD47, LY96, TSG101 | BLM 1467/4885LMNA 2681/4885PTPN1 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.